Content continues after advertisement

Drug Interactions in Polypharmacy

Lauren A. Trepanier, DVM, PhD, DACVIM, DACVCP, University of Wisconsin–Madison

Pharmacology & Medications

|June 2013|Peer Reviewed

Sign in to Print/View PDF

Drug Interactions in Polypharmacy

You have asked...What are some of the common drug interactions in polypharmacy?

The expert says...

Numerous human drug interactions can occur during absorption, at the target site, or during hepatic or renal elimination, and may lead to loss of efficacy or increased toxicity.1 Many of these interactions are likely to occur in dogs and cats as well (see Drug Interactions in Humans That May Affect Dogs & Cats), although relatively few veterinary studies have been conducted. Several key veterinary drugs have high interaction potential.

Related Article: Corticosteroid & Nonsteroidal Antiinflammatory Drug Interactions

Cimetidine
Cimetidine, a histamine (H2)-blocker, is a potent inhibitor of several families of cytochrome P450 enzymes and can also inhibit transporter pumps and decrease the renal excretion of some drugs, including clearance of many drugs, such as theophylline, lidocaine, midazolam, and propranolol.2

Because of many potential cimetidine interactions, alternative H2-blockers such as famotidine, nizatidine, or ranitidine (not a clinically significant P450 inhibitor at therapeutic concentrations in humans)3 should be chosen instead. Ranitidine and nizatidine have the added advantage of prokinetic effects, which may counteract gastric atony in clinically ill patients.

Sucralfate
Sucralfate and aluminum-containing antacids form complexes with many drugs in the GI tract, markedly decreasing drug absorption. For example, in humans, absorption of ciprofloxacin, a fluoroquinolone, is reduced by 96% when given with sucralfate; if ciprofloxacin is given 2 hours after sucralfate, absorption can still be reduced by less than 50% but is less impaired (about 17%) if ciprofloxacin is given 2 hours before sucralfate.4,5

Sucralfate and other aluminum-containing drugs also inhibit the absorption of tetracycline, theophylline, and digoxin.6 These physicochemical interactions can also occur in dogs and cats. Because coordinating dosing at home can be difficult, sucralfate should not be used for outpatients being administered oral drugs. The exception is H2-blockers, for which sucralfate slows but does not decrease the extent of absorption. In humans, sucralfate and H2-blockers are given simultaneously without loss of efficacy6; this may apply to dogs and cats with suspected or documented gastric ulceration.

Related Article: Noncutaneous Adverse Drug Reactions - Part 1

Ketoconazole
Ketoconazole, an antifungal, inhibits a specific cytochrome P450 enzyme family (CYP3A) that has a wide substrate range and high potential for drug–drug interactions in humans, dogs, and cats. Ketoconazole inhibits P-glycoprotein, the important drug efflux transporter in the GI tract, kidney(s), biliary tree, and brain. Therefore, ketoconazole can decrease the bioavailability and/or clearance of many drugs.

For example, ketoconazole increases blood cyclosporine concentrations, which can allow lower therapeutic doses of cyclosporine (less expensive for clients). The recommended starting doses are cyclosporine at 2.5 to 5 mg/kg q12–24h (depending on disease severity) and ketoconazole at 5 to 10 mg/kg q24h.7 Trough cyclosporine concentrations can be measured at a steady state after 5 days of treatment.7

Ketoconazole also doubles ivermectin exposure (based on area under the curve) in dogs.8 Neurologic toxicity has not been reported but could occur if ketoconazole was combined with high doses of ivermectin (eg, in treating sarcoptic mange) or given to P-glycoprotein–deficient (ABCB1 deletion) breeds.

Other drugs that show impaired clearance with ketoconazole include clomipramine, amitriptyline, midazolam, alprazolam, zonisamide, cisapride, fluoxetine, and vinblastine.9 Like ketoconazole, itraconazole inhibits the cytochrome P450 metabolism of cyclosporine, midazolam, alprazolam, and zonisamide in humans.9

Fluoroquinolones
Fluoroquinolone antibiotics inhibit the clearance of theophylline. This has led to theophylline toxicosis in humans and is attributed to inhibition of the cytochrome P450 enzyme CYP1A2. In dogs, enrofloxacin can lead to 30% to 50% higher plasma theophylline concentrations,10 and marbofloxacin at 5 mg/kg can increase theophylline exposure by about 28%.11

Oral absorption of fluoroquinolones is impaired by drugs that contain divalent or trivalent cations, such as aluminum (eg, sucralfate, aluminum hydroxide, aluminum carbonate), calcium carbonate, oral zinc, oral iron, and magnesium (eg, vitamin supplements). This can lead to decreased fluoroquinolone concentrations and potential therapeutic failure.

Omeprazole
Omeprazole, a proton-pump inhibitor, inhibits some cytochrome P450 enzymes in humans (primarily CYP2C19) and may inhibit the clearance of some drugs, including diazepam, midazolam, warfarin, and carbamazepine. Omeprazole also impairs conversion of clopidogrel, an antiplatelet agent, to its active metabolite in humans, leading to decreased antiplatelet efficacy and increased risk for ischemic cardiac events.12 Omeprazole may also lead to digoxin toxicosis, possibly via inhibition of P-glycoprotein efflux of digoxin.13

As a potent inhibitor of gastric acid secretion, all proton pump blockers can decrease the absorption of compounds that require an acidic pH for optimal absorption, including iron supplements, oral zinc, ketoconazole, and itraconazole. This same interaction also applies to H2-blockers (eg, famotidine). Discontinuing antacids when ketoconazole or itraconazole is being given may be wise. Alternatively, if antacids cannot be discontinued, fluconazole can be considered if indicated, as fluconazole absorption is not affected by changes in gastric pH.14,15 

Phenobarbital
Phenobarbital, an anticonvulsant, is a major P450 enzyme inducer in humans and dogs. Phenobarbital accelerates the metabolism of many drugs, including ketoconazole, clomipramine, and lidocaine. Phenobarbital also accelerates the clearance of mitotane; therefore, dogs on both phenobarbital and mitotane often need much higher loading and maintenance doses of mitotane for hyperadrenocorticism treatment. In cats, however, phenobarbital causes minimal cytochrome P450 enzyme induction,16,17 and P450-mediated drug interactions with phenobarbital are unlikely.

Clomipramine
Clomipramine, a tricyclic antidepressant, inhibits both norepinephrine and serotonin reuptake. Clomipramine can lead to serotonin accumulation and serotonin syndrome (clinically seen as twitching, tremor, tachycardia, myoclonic movements, and hyperthermia) in humans when used in combination with monoamine oxidase inhibitors (MAOIs, which decrease the breakdown of serotonin) or serotonin reuptake inhibitors, which increase synaptic serotonin concentrations. Deaths have been reported in humans given clomipramine plus MAOIs—a well-established interaction. Veterinary MAOIs include l-deprenyl (selegiline) and amitraz.

Other drugs that affect serotonin include tramadol and dextromethorphan (both of which inhibit serotonin reuptake). However, the interaction potential with these weaker serotonergic drugs appears much lower in humans.

Closing Remarks
Based on what is known for human patients, these drugs pose reasonable risk for adverse drug interactions in dogs and cats. The accompanying drug history should be reviewed carefully when these drugs are administered. Veterinarians should obtain a complete and updated drug history at each office visit, but this is especially important when new drugs are being prescribed or a patient is not well.

Useful Resources to Help Screen for Potential Drug Interactions

  • PubMed - Can be used to search for both veterinary and human drug studies

References

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast

Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Privacy Policy (Updated 05/08/2018) Terms of Use (Updated 05/08/2018)